Skip to main content
letter
. 2022 Apr 29;17(6):1845–1847. doi: 10.1007/s11739-022-02989-9

Fig. 1.

Fig. 1

MS course of the patient: the trend over time of the clinical and radiological activity of the disease, the DMDs and the disability levels expressed by the EDSS. MS multiple sclerosis, DMDs disease-modifying drugs, EDSS expanded disability status scale, IFN interferon, DMF dimethyl fumarate